FIG 2.

Clinical and microbiological outcomes following various therapeutic regimes. CoTGC, active tigecycline-based combination therapy (n = 10); AMG, active aminoglycoside monotherapy (n = 17); Com, active drug combination therapy (including tigecycline-based combination therapy; n = 20); Carb, active carbapenem monotherapy (n = 25); Non-A, nonactive drug therapy (n = 66); MoTGC, active tigecycline monotherapy (n = 31); MEM, meropenem MIC values. *, including inactive and active carbapenem administration.